CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 72 enrolled
Drug / intervention
Ziprasidone +2 moredrug
Likely dose
Ziprasidone 160mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00340379
NCT00340379Phase 3Completed
CompareCT.gov

A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol

Duke University·interventional·Posted Jun 21, 2006·Updated Aug 19, 2014

In Brief

A Phase 3 clinical trial evaluating Ziprasidone, Sertraline, and 1 other intervention for Affective Disorders. Completed, enrolled 72 participants across 3 sites in 3 countries.

Detailed Summary

The purpose of this study is to compare ziprasidone (Geodon) monotherapy for the treatment of psychotic major depression (PMD)with an antidepressant/antipsychotic combined therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAffective Disorders
CountriesEgypt, India, United States
CollaboratorsPfizer, National Institute of Mental Health and Neuro Sciences, India

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 21, 2006
Enrollment StartApr 1, 2003
Primary CompletionAug 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.0 years ago

Interventions

Ziprasidonedrug

Target dosage 120-160mg/day based on tolerance

Sertralinedrug

Target dosage 150-200mg/day based on tolerance.

Haloperidoldrug

Target dosage 6-8mg/day based on tolerance.